A PYMNTS Company

U.S.: FTC pulls antitrust probe over Yasmin deals

By  |  October 4, 2012

According to the FTC, the Bayer Schering Pharma AG and Barr Laboratories Inc. settlements, which relate to patent infringement allegations over Bayer’s Yasmin birth control drug, will no longer be subject to antitrust scrutiny. The FTC is also closing an investigation into the deals that aimed to monitor competititve behavior.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Full Content: Law360

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.